Full Press Release Details
Collegium Appoints Rita Balice-Gordon
to its Board of Directors
STOUGHTON, Mass., September 25, 2020 -- Collegium
Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain
management, today announced the appointment of Rita Balice-Gordon to its Board of Directors, effective September 24, 2020.
"Collegium is honored to welcome Rita to our Board of
Directors," said Mike Heffernan, Founder and Chairman of the Board of Collegium. "Rita's impressive scientific
expertise and industry experience will be incredibly valuable for the Company. We are confident that she will make meaningful contributions
to our Board of Directors and that Collegium will benefit from her insights as we continue our commitment to leadership in responsible
"I am excited for the opportunity to join Collegium's
Board during this important time in the Company's evolution, and I look forward to working with the Board and the management
team to make a positive difference in the lives of people suffering from pain," said Dr. Balice-Gordon.
About Rita Balice-Gordon
Rita Balice-Gordon, Ph.D., has served
as the Chief Scientific Officer of Muna Therapeutics, a newly formed biotech company focused on developing novel therapeutics for
patients with neurodegenerative diseases, since May 2020, and is an entrepreneur-in-residence at Novo Seeds since August 2020.
Previously, Dr. Balice-Gordon served in scientific roles of increasing responsibility at Sanofi, Inc., most recently as Global
Head of Rare and Neurological Diseases. Prior to joining Sanofi, Dr. Balice-Gordon led the psychiatry and pain drug discovery portfolios
as Vice President in the Neuroscience and Pain Research Unit at Pfizer, Inc. Earlier in her career, Dr. Balice-Gordon was Professor
of Neuroscience and Chair of the Neuroscience Graduate Group at the University of Pennsylvania Perelman School of Medicine, where
she currently holds an appointment as Adjunct Professor in the Department of Neuroscience.
Dr. Balice-Gordon has authored more
than 100 scientific papers, received numerous accolades for her work in the field of neuroscience and has chaired or served on
many NIH, national and international committees. She received her B.A. degree in Biological Sciences from Northwestern University
and her Ph.D. in Neurobiology from the University of Texas at Austin.
About Collegium Pharmaceutical, Inc.
Collegium is a specialty pharmaceutical company committed to
being the leader in responsible pain management. Collegium's headquarters are located in Stoughton, Massachusetts. For more
information, please visit the company's website at www.collegiumpharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts,"
"forecasts," "believes," "potential," "proposed," "continue," "estimates,"
"anticipates," "expects," "plans," "intends," "may," "could," "might,"
"should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements.
Management's expectations and, therefore, any forward-looking statements in this press release could also be affected by risks
and uncertainties relating to a number of other factors, including the impact of the COVID-19 pandemic on our ability to conduct
our business, reach our customers, and supply the market with our products. This and other risks are described under the heading
"Risk Factors" in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2020 and other filings with the SEC.
Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no
obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the
date of this press release.